Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
NCT01675765
Completed
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin). CRS-207 is a weakened (attenuated) form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. CRS-207 has been engineered to elicit an immune response against... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2020
Locations: University of California at San Francisco, San Francisco, California +4 locations
Conditions: Malignant Pleural Mesothelioma
Register for Updates
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer
NCT01697293
Terminated
This phase I/II trial studies the side effects and the best dose of triciribine phosphate when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cyclophosphamide, work in different ways to stop... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
NCT00101010
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II... Read More
Gender:
ALL
Ages:
61 years and above
Trial Updated:
09/22/2020
Locations: Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith, Arkansas +6 locations
Conditions: Lymphoma
Register for Updates
Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma
NCT02541565
Completed
This pilot phase I trial studies the side effects of pembrolizumab and combination chemotherapy in treating patients with previously untreated diffuse large B-cell lymphoma or grade 3b follicular lymphoma. Monoclonal antibodies, such as pembrolizumab and rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of canc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/22/2020
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage I Follicular Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage II Follicular Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage III Follicular Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage IV Follicular Lymphoma
Register for Updates
Comparing Therapies for the Treatment of Severe Aplastic Anemia
NCT00001626
Completed
Severe Aplastic Anemia (SAA) is a rare and very serious blood disorder in which the bone marrow stops producing the cells which make up blood; red blood cells, white blood cells, and platelets. Researchers believe this is caused by an autoimmune reaction, a condition in which the natural defense system of the body begins attacking itself. In SAA the immune system begins attacking the bone marrow. Red blood cells are responsible for carrying oxygen to all of the organ systems in the body, and lo... Read More
Gender:
ALL
Ages:
Between 15 years and 110 years
Trial Updated:
09/21/2020
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Severe Aplastic Anemia (SAA)
Register for Updates
Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy
NCT00574587
Completed
Vorinostat is a histone deacetylase (HDAC) inhibitor which is approved by the U.S. Food and Drug Administration for the treatment of a rare type of cancer involving the skin (cutaneous T cell lymphoma), but not for breast cancer. HDAC inhibitors work by unsilencing tumor suppressor genes and other genes in the cancer cells that are repressed; when the genes are turned back on by the drug, it leads to death of the cancer cells. HDAC inhibitors such as vorinostat have been shown to enhance the eff... Read More
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
09/18/2020
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Breast Cancer
Register for Updates
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
NCT01516307
Completed
The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable disease or response to treatment.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
09/14/2020
Locations: The University of Alabama at Birmingham (UAB), Birmingham, Alabama +42 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222
Completed
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy given with or without epoetin alfa in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer.
Gender:
FEMALE
Ages:
60 years and below
Trial Updated:
09/11/2020
Locations: Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas +77 locations
Conditions: Breast Cancer
Register for Updates
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
NCT00137111
Completed
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Gender:
ALL
Ages:
Between 12 months and 18 years
Trial Updated:
09/09/2020
Locations: St Jude Children's Research Hospital, Memphis, Tennessee +1 locations
Conditions: Lymphoblastic Leukemia, Acute
Register for Updates
Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
NCT02502864
Completed
The purpose of this study is to adjust the amount of docetaxel participants receive based on the level of docetaxel measured in their blood. This method of dose adjustment is called pharmacokinetic (PK)-adjusted docetaxel. The researchers believe that adjusting the dose of docetaxel using this method will lessen the side effects associated with docetaxel in cancer treatment.
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
09/09/2020
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Breast Cancer, Breast Cancer Female
Register for Updates
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
NCT00625898
Terminated
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2020
Locations: University of Alabama at Birmingham, Birmingham, Alabama +648 locations
Conditions: Breast Cancer
Register for Updates
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
NCT00309842
Completed
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an imm... Read More
Gender:
ALL
Ages:
55 years and below
Trial Updated:
09/09/2020
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Register for Updates